Cenix BioScience and collaborators awarded research grant under InnoRegio program of German Federal Ministry of Education and Research (BMBF) for diversification of RNAi technologies.
 

Dresden, Germany, August 2, 2004  - Cenix BioScience GmbH, together with the Max Planck Institute for Cell Biology and Genetics (MPI-CBG, Dresden) and Evotec Technologies GmbH, today announced that it has secured another research grant under the InnoRegio BioMeT program of the German Federal Ministry of Education and Research (BMBF), created to support high-tech research & development in biotechnology and medicine in the Dresden region.

The collaborative project, for which BioMeT support to Cenix will total 464,000 Euro from 2004 to 2006, is named "Diversification of applications for the HT-RNAi technology", and will enable the co-applicants to jointly diversify RNAi study strategies using cultured human cell models combined with high content microscopy-based assays. The funds will cover a wide range of research & development activities aiming to explore siRNA screening in disease relevant cells and establish new assay protocols, including pathway profiling and drug mode-of-action approaches.